Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. Mindset Pharma Inc.
  6. News
  7. Summary
    MSET   CA60268M1023

MINDSET PHARMA INC.

(MSET)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Mindset Pharma Inc. Announces Further Preclinical Results Demonstrating Strong Efficacy and Improved Safety Profile for its 5-MeO-DMT-Inspired Drug Candidate, MSP-4018

09/20/2021 | 07:30am EST

Mindset Pharma Inc. announced that preclinical proof-of-concept data comparing its clinical candidate, MSP-4018, against 5-MeO-DMT further demonstrated strong efficacy and an improved safety profile as a next generation psychedelic medicine. Mindset’s Family 4 compounds are DMT and 5-MeO-DMT-inspired novel drug candidates that offer a broad range of pharmacological diversity suitable for in-clinic settings. The Company has run a battery of specialized in-vitro and in-vivo tests on its patent-pending novel compounds to select the optimal psychedelic drug candidates for progressing towards human clinical trials.


ę S&P Capital IQ 2021
All news about MINDSET PHARMA INC.
11/29Mindset to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conferenc..
GL
11/08Mindset Pharma Announces Poster Presentation of Preclinical Data for Benchmarking Next-..
GL
10/26Mindset Pharma Reports Fiscal Year 2021 Financial Results and Provides Corporate Update
AQ
10/26Mindset Pharma Inc Reports Earnings Results for the Fiscal Year Ended June 30, 2021
CI
10/26MINDSET PHARMA TO PARTICIPATE IN WON : Miami on November 8-9, 2021
GL
10/18KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Vie..
AQ
10/14MINDSET PHARMA : Expands Benchmarking Data for First Generation Psychedelics Through the C..
AQ
10/14Mindset Pharma Expands Benchmarking Data for First Generation Psychedelics Through the ..
CI
10/11KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th
AQ
09/29MINDSET PHARMA EXPANDS PIPELINE : Identifies Additional Next Generation 5-MeO-DMT-Inspired..
GL
More news
Financials
Sales 2022 - - -
Net income 2022 -15,6 M -12,2 M -12,2 M
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 61,0 M 47,6 M 47,8 M
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees -
Free-Float -
Chart MINDSET PHARMA INC.
Duration : Period :
Mindset Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
James Andre Charles Lanthier Chief Executive Officer
Arvin Ramos Chief Financial Officer
Richard J. Patricio Chairman
Joseph Araujo Director & Chief Science Officer
James Christopher Passin Director
Sector and Competitors
1st jan.Capi. (M$)
MINDSET PHARMA INC.-26.60%48
MODERNA, INC.237.35%142 893
LONZA GROUP AG30.63%59 859
IQVIA HOLDINGS INC.44.63%49 504
SEAGEN INC.-8.64%29 257
CELLTRION, INC.-42.34%23 827